Private Equity
New York-based NS1, a provider of next generation DNS and application traffic management solutions, has raised $33 million in Series C funding. Dell Technologies Capital led the round with participation from Cisco Investments, Deutsche Telekom Capital Partners, Entrée Capital, Flybridge Capital Partners, GGV Capital, Mango Capital, Salesforce Ventures, Sigma Prime Ventures, Telstra Ventures and Two Sigma Ventures.
1 min read · 03 October 2019
Greylock Partners announced that it has hired David Wadhwani as a venture partner. Wadhwani was most recently CEO of AppDynamics, which Greylock backed. Cisco purchased AppDynamics in 2017 for $3.7 billion days prior to its scheduled IPO. Prior to AppDynamics, Wadhwani was with Adobe.
1 min read · 03 October 2019
Woburn, Massachusetts-based Frequency Therapeutics, a biotech firm, has raised about $84 million for its IPO after pricing its 6 million share at $14 per share. The stock began trading October 3, 2019 on the NASDAQ under the ticker symbol "FREQ." J.P. Morgan, Goldman Sachs and Cowen are the lead underwriters. Frequency's pre-IPO backers include Perceptive Advisors.
3 min read · 03 October 2019
Menlo Park, California-based Adicet Bio Inc, a biopharmaceutical company, has raised $80 million in Series B financing. The investors include aMoon2 Fund, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Innovation – JJDC Inc, Samsung Venture Investment Corporation, OrbiMed, Novartis Venture Fund and Pontifax.
1 min read · 03 October 2019
Super{set} said Oct. 2 that it secured $65 million in funding. Super{set}, a San Francisco startup studio that aims to launch data-driven enterprise tech companies, did not disclose investors.
4 min read · 03 October 2019
Seattle-based vaccines developer Icosavax has secured $52 million in Series A funding. Qiming Venture Partners USA led the round with participation from Adams Street Partners, Sanofi Ventures and NanoDimension.
1 min read · 03 October 2019
Longliv Ventures is investing $5 million in DayTwo, a microbiome human discovery platform. DayTwo's other investors include Cathay Innovation and Samsung NEXT.
1 min read · 03 October 2019
South San Francisco-based Tenaya Therapeutics Inc, a provider of curative therapies that target the underlying causes of heart disease, has secured $92 million in Series B financing. Casdin Capital led the round with participation from other investors that included GV and The Column Group.
1 min read · 03 October 2019
AmacaThera, a Toronto-based developer of injectable hydrogel technology for medical applications, has secured US$3.6 million in seed funding. The investors were Sprout BioVentures/ Viva Biotech, Grey Sky Venture Partners and Toronto-based Lumira Ventures. AmacaThera is currently a resident company at the Johnson & Johnson Innovation – JLABS incubator.
1 min read · 03 October 2019
Cambridge, Massachusetts-based Verve Therapeutics, a next-generation cardiovascular company, has named Dr. Andrew Bellinger as chief scientific officer. Dr. Bellinger is a general cardiologist at Brigham and Women’s Hospital. Verve’s backers include GV, ARCH Venture Partners, F-Prime Capital and Biomatics Capital.
3 min read · 03 October 2019
